173 related articles for article (PubMed ID: 26471883)
1. Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score.
Pastori D; Farcomeni A; Poli D; Antonucci E; Angelico F; Del Ben M; Cangemi R; Tanzilli G; Lip GY; Pignatelli P; Violi F
Intern Emerg Med; 2016 Mar; 11(2):199-204. PubMed ID: 26471883
[TBL] [Abstract][Full Text] [Related]
2. Adverse cardiovascular outcomes in atrial fibrillation: Validation of the new 2MACE risk score.
Polovina M; Đikić D; Vlajković A; Vilotijević M; Milinković I; Ašanin M; Ostojić M; Coats AJS; Seferović PM
Int J Cardiol; 2017 Dec; 249():191-197. PubMed ID: 28986061
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation.
Rivera-Caravaca JM; Marín F; Esteve-Pastor MA; Raña-Míguez P; Anguita M; Muñiz J; Cequier Á; Bertomeu-Martínez V; Valdés M; Vicente V; Lip GYH; Roldán V
Am J Cardiol; 2017 Dec; 120(12):2176-2181. PubMed ID: 29111209
[TBL] [Abstract][Full Text] [Related]
4. Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry.
Ding WY; Fawzy AM; Romiti GF; Proietti M; Pastori D; Huisman MV; Lip GYH;
J Thromb Thrombolysis; 2024 Jan; 57(1):39-49. PubMed ID: 37566295
[TBL] [Abstract][Full Text] [Related]
5. Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study.
Sanmartín Fernández M; Anguita Sánchez M; Arribas F; Barón-Esquivias G; Barrios V; Cosin-Sales J; Esteve-Pastor MA; Freixa-Pamias R; Lekuona I; Pérez-Cabeza AI; Ureña I; Vázquez Rodríguez JM; Rafols Priu C; Marin F
Cardiol J; 2022; 29(4):601-609. PubMed ID: 35621092
[TBL] [Abstract][Full Text] [Related]
6. Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors.
Pastori D; Pignatelli P; Angelico F; Farcomeni A; Del Ben M; Vicario T; Bucci T; Raparelli V; Cangemi R; Tanzilli G; Lip GYH; Violi F
Chest; 2015 Jun; 147(6):1644-1650. PubMed ID: 25429521
[TBL] [Abstract][Full Text] [Related]
7. Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation.
Pastori D; Pignatelli P; Saliola M; Carnevale R; Vicario T; Del Ben M; Cangemi R; Barillà F; Lip GY; Violi F
Int J Cardiol; 2015 Dec; 201():513-6. PubMed ID: 26318513
[TBL] [Abstract][Full Text] [Related]
8. Association of metabolic syndrome with non-thromboembolic adverse cardiac outcomes in patients with atrial fibrillation.
Polovina M; Hindricks G; Maggioni A; Piepoli M; Vardas P; Ašanin M; Ðikic D; Ðuricic N; Milinkovic I; Seferovic PM
Eur Heart J; 2018 Dec; 39(45):4030-4039. PubMed ID: 30101326
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients.
Pastori D; Rivera-Caravaca JM; Esteve-Pastor MA; Roldán V; Marín F; Pignatelli P; Violi F; Lip GYH
Circ J; 2018 Apr; 82(5):1286-1292. PubMed ID: 29553090
[TBL] [Abstract][Full Text] [Related]
10. Effects of Atrial Fibrillation and Chronic Kidney Disease on Major Adverse Cardiovascular Events.
Ding WY; Lip GYH; Pastori D; Shantsila A
Am J Cardiol; 2020 Oct; 132():72-78. PubMed ID: 32773222
[TBL] [Abstract][Full Text] [Related]
11. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
[TBL] [Abstract][Full Text] [Related]
12. Pilot Study on the Role of Circulating miRNAs for the Improvement of the Predictive Ability of the 2MACE Score in Patients with Atrial Fibrillation.
Rivera-Caravaca JM; Teruel-Montoya R; Roldán V; Cifuentes-Riquelme R; Crespo-Matas JA; de Los Reyes-García AM; Águila S; Fernández-Pérez MP; Reguilón-Gallego L; Zapata-Martínez L; García-Barberá N; Vicente V; Marín F; Martínez C; González-Conejero R
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33198388
[No Abstract] [Full Text] [Related]
13. Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation.
Pastori D; Pignatelli P; Farcomeni A; Cangemi R; Hiatt WR; Bartimoccia S; Nocella C; Vicario T; Bucci T; Carnevale R; Lip GY; Violi F
Am Heart J; 2015 Sep; 170(3):490-7.e1. PubMed ID: 26385032
[TBL] [Abstract][Full Text] [Related]
14. Risks of Death and Stroke in Patients Undergoing Hemodialysis With New-Onset Atrial Fibrillation: A Competing-Risk Analysis of a Nationwide Cohort.
Shih CJ; Ou SM; Chao PW; Kuo SC; Lee YJ; Yang CY; Tarng DC; Lin CC; Huang PH; Li SY; Chen YT
Circulation; 2016 Jan; 133(3):265-72. PubMed ID: 26680239
[TBL] [Abstract][Full Text] [Related]
15. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
[TBL] [Abstract][Full Text] [Related]
16. Mitral annular calcification predicts cardiovascular morbidity and mortality in middle-aged patients with atrial fibrillation: the Belgrade Atrial Fibrillation Study.
Potpara TS; Vasiljevic ZM; Vujisic-Tesic BD; Marinkovic JM; Polovina MM; Stepanovic JM; Stankovic GR; Ostojic MC; Lip GYH
Chest; 2011 Oct; 140(4):902-910. PubMed ID: 21436252
[TBL] [Abstract][Full Text] [Related]
17. Atrial fibrillation significantly increases total mortality and stroke risk beyond that conveyed by the CHADS2 risk factors.
Crandall MA; Horne BD; Day JD; Anderson JL; Muhlestein JB; Crandall BG; Weiss JP; Osborne JS; Lappé DL; Bunch TJ
Pacing Clin Electrophysiol; 2009 Aug; 32(8):981-6. PubMed ID: 19659615
[TBL] [Abstract][Full Text] [Related]
18. Serum NOX2 and urinary isoprostanes predict vascular events in patients with atrial fibrillation.
Pignatelli P; Pastori D; Carnevale R; Farcomeni A; Cangemi R; Nocella C; Bartimoccia S; Vicario T; Saliola M; Lip GY; Violi F
Thromb Haemost; 2015 Mar; 113(3):617-24. PubMed ID: 25392853
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation.
Melgaard L; Gorst-Rasmussen A; Lane DA; Rasmussen LH; Larsen TB; Lip GY
JAMA; 2015 Sep; 314(10):1030-8. PubMed ID: 26318604
[TBL] [Abstract][Full Text] [Related]
20. Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study.
Raparelli V; Pastori D; Pignataro SF; Vestri AR; Pignatelli P; Cangemi R; Proietti M; Davì G; Hiatt WR; Lip GYH; Corazza GR; Perticone F; Violi F; Basili S;
Intern Emerg Med; 2018 Aug; 13(5):651-660. PubMed ID: 29582316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]